Daré Bioscience, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Daré Bioscience, Inc.
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
- Medical Devices
- Drug Delivery
- Other Names / Subsidiaries
- Cerulean Pharma Inc. (CERU)
- Dare Bioscience, Inc.
- Microchips Biotech, Inc.
- Pear Tree Pharmaceuticals, Inc. Tempo Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.